**BACKGROUND**

HHV-8, also designated Kaposi’s sarcoma-associated herpesvirus, is associated with multicentric Castleman’s disease and primary effusion lymphoma, a rare type of non-Hodgkin lymphoma affecting the body cavities. HHV-8 K14 is expressed at the surfaces of infected cells solely during the lytic cycle. It interacts with human CD200R, a receptor expressed on myeloid cells that is involved in locally restricting macrophage activation. The interaction of HHV-8 K14 with CD200R allows the protein to locally restrain macrophage activation by inhibiting TNFα production. HHV-8 encodes a viral-cyclin that is homologous to cellular D-type cyclins, a class of positive cell cycle mediators that are physiologically regulated by the p27 cell cycle inhibitor. HHV-8 cyclin is not sensitive to p27, however, which may explain the coexistence of p27 and high proliferative index of HHV-8 observed in individuals with primary effusion lymphoma (PEL).

**REFERENCES**


**SOURCE**

HHV-8 (LN35) is a rat monoclonal antibody raised against recombinant HHV-8 corresponding to the latent nuclear antigen 1 molecule of HHV 8.

**PRODUCT**

Each vial contains 250 µl culture supernatant containing IgG2c with < 0.1% sodium azide.

**APPLICATIONS**

HHV-8 (LN35) is recommended for detection of HHV-8 by immunofluorescence (starting dilution to be determined by researcher, dilution range 1:10-1:200) and immunohistochemistry (including paraffin-embedded sections) (starting dilution to be determined by researcher, dilution range 1:10-1:200).

**STORAGE**

For immediate and continuous use, store at 4°C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

**RESEARCH USE**

For research use only, not for use in diagnostic procedures.

**PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.